Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia 2 Thrombocythemia, Essential 1 Primary Myelofibrosis 1 Polycythemia Vera 1 Neuroblastoma 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Lymphoma, Primary Effusion 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1 Leukemia, Myeloid, Acute 1 Leukemia, Myeloid, Accelerated Phase 1 Hematologic Diseases 1 Graft vs Host Disease 1 Congenital Abnormalities 1 Blast Crisis 1

Interventions

Vincristine 3 Rituximab 3 Prednisone 3 Etoposide 3 Doxorubicin 3 Cyclophosphamide 3 varlilumab 1 prednylidene 1 pomalidomide 1 liposomal doxorubicin 1 etoposide phosphate 1 deltacortene 1 Vorinostat 1 Ultrasonography 1 Nivolumab 1 Lenalidomide 1 Immunoglobulin G 1 Endoscopy 1 Electrocardiography 1 Echocardiography 1 Disulfides 1 CT-P10 1 Bronchoscopy 1 Bone Marrow Transplantation 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NIH × Lymphoma, Primary Effusion × Bone Marrow Transplantation × Clear all

NCT04975698 2026-03-25

BMTCTN1903

National Heart, Lung, and Blood Institute (NHLBI)

Phase 2 Completed

Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon ⚡